Proteogenomic Subtypes of Chronic Liver Disease: A Comprehensive Review for Clinicians

Abstract

Chronic liver disease (CLD) encompasses a spectrum of heterogeneous conditions with diverse clinical presentations and outcomes. Recent advances in proteogenomics have enabled deeper characterization of molecular subtypes within CLD, revealing distinct biological mechanisms and potential therapeutic targets. This article provides an extensive evidence-based review of proteogenomic subtypes of chronic liver disease, emphasizing their epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, recent advances, guideline recommendations, and clinical implications for hepatologists and healthcare professionals.

Introduction

Chronic liver disease remains a significant global health burden, resulting in considerable morbidity and mortality. Traditional classification of CLD has relied on etiology and histopathological features; however, the emergence of proteogenomics—integrating proteomic and genomic data—has transformed our understanding of the molecular subtypes underlying CLD. These advances facilitate the identification of patient-specific disease mechanisms, prognostic biomarkers, and personalized therapeutic strategies, marking a paradigm shift in hepatology. This review synthesizes current literature on proteogenomic subtypes of CLD, bridging cutting-edge research with clinical practice.

Epidemiology / Disease Burden

Chronic liver disease affects over 1.5 billion individuals worldwide, with etiologies including viral hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, autoimmune hepatitis, and genetic disorders. The disease burden varies regionally, with NAFLD emerging as the most prevalent etiology in high-income countries, while viral hepatitis dominates in lower-income regions. The advent of proteogenomic profiling has revealed that these epidemiological patterns mask significant intragroup heterogeneity, as patients with similar etiologies may have distinct molecular subtypes influencing disease progression, response to therapy, and risk of hepatocellular carcinoma (HCC).

Pathophysiology

Proteogenomic subtyping integrates high-throughput sequencing and proteomic analyses to delineate molecular signatures within CLD. Genomic alterations—such as single nucleotide polymorphisms, copy number variations, and epigenetic modifications—interact with post-translational protein modifications to shape disease phenotypes. For example, recent studies have identified subtypes of NAFLD characterized by unique transcriptomic and proteomic profiles, including altered lipid metabolism, inflammation, and fibrogenesis pathways. In viral hepatitis, proteogenomic analysis has uncovered specific immune-related signatures and viral-host protein interactions that may predict progression to cirrhosis or HCC. Such mechanistic insights are crucial for stratifying patients and tailoring interventions.

Risk Factors

Traditional risk factors for CLD—such as obesity, diabetes, alcohol consumption, viral infections, and genetic predisposition—interact with underlying molecular pathways identified through proteogenomics. For instance, certain polymorphisms in PNPLA3, TM6SF2, and MBOAT7 genes have been linked to specific proteogenomic subtypes with heightened susceptibility to steatosis or fibrosis. Environmental exposures and metabolic comorbidities modulate proteomic expression, contributing to inter-individual variability in disease trajectory and therapeutic response. Recognizing these risk factors in the context of proteogenomic subtypes enhances risk stratification and informs preventive strategies.

Clinical Features

While clinical manifestations of CLD—such as fatigue, jaundice, ascites, hepatic encephalopathy, and variceal bleeding—are well recognized, proteogenomic subtyping reveals that patients with similar phenotypic presentations may harbor distinct molecular drivers. Subtypes linked to heightened inflammatory or fibrogenic activity may progress more rapidly and respond differently to interventions. Recent cohort studies demonstrate that integrating proteogenomic data with conventional clinical assessment enables earlier identification of high-risk patients, prediction of decompensation, and personalization of monitoring protocols.

Diagnosis

Diagnosis of proteogenomic subtypes in CLD relies on advanced molecular profiling techniques, including next-generation sequencing (NGS), mass spectrometry-based proteomics, and integrated bioinformatic pipelines. While liver biopsy remains the gold standard for histological evaluation, non-invasive biomarkers derived from proteogenomic analyses—such as circulating protein signatures or cell-free DNA—are increasingly available. Multiparametric risk models incorporating proteogenomic data have demonstrated superior accuracy in predicting fibrosis stage, disease progression, and HCC risk compared to traditional scoring systems.

Treatment & Management

Management of CLD is evolving in parallel with our understanding of its molecular heterogeneity. Standard therapies—including antiviral agents, metabolic modulation, immunosuppression, and antifibrotic drugs—are being complemented by precision medicine approaches targeting specific proteogenomic subtypes. For example, patients with NAFLD subtypes driven by lipid metabolic dysfunction may benefit from PPAR agonists or SGLT2 inhibitors, while those with immune-dominant signatures may respond to immunomodulatory agents. Proteogenomic profiling also informs risk-adapted surveillance and transplant prioritization strategies.

Recent Advances / Emerging Therapies

Recent breakthroughs in single-cell proteogenomics and spatial transcriptomics have enabled unprecedented dissection of liver cellular heterogeneity, uncovering novel therapeutic targets. Clinical trials are underway evaluating agents targeting subtype-specific pathways, such as inhibitors of TGF-β signaling for fibrogenic subtypes or immune checkpoint inhibitors for immune-enriched HCC. Artificial intelligence-driven integration of proteogenomic, clinical, and imaging data is accelerating biomarker discovery and predictive modeling, paving the way for individualized care pathways in CLD.

Guideline Recommendations

Recognizing the clinical utility of proteogenomic subtyping, recent guidelines from hepatology societies advocate for the incorporation of molecular profiling in selected patients with CLD, particularly those at high risk for progression or with atypical clinical courses. Recommendations emphasize a multidisciplinary approach, combining conventional risk assessment with molecular diagnostics to guide therapy selection, surveillance intervals, and enrollment in precision medicine trials. Ongoing updates to guidelines are expected as the clinical validity and utility of proteogenomic testing continue to expand.

Conclusion

The integration of proteogenomic subtyping into the clinical management of chronic liver disease marks a transformative advance in hepatology. By elucidating the molecular underpinnings of disease heterogeneity, proteogenomics enables personalized risk stratification, targeted therapy, and improved patient outcomes. Continued research, multidisciplinary collaboration, and guideline evolution will be essential to realize the full potential of proteogenomic medicine in improving the care of patients with chronic liver disease.